The effect of different doses of near infrared light on dopaminergic cell survival and gliosis in MPTP-treated mice

International Journal of Neuroscience

Volumn 126, Issue 1, 2016, Pages 76-87

  El Massri, Nabil ^a   Johnstone, Daniel M ^a   Peoples, Cassandra L ^a   Moro, Cécile ^b   Reinhart, Florian ^b   Torres, Napoleon ^b   Stone, Jonathan ^a   Benabid, Alim Louis ^b   Mitrofanis, John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

neuroprotection; substantia nigra; tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; TYROSINE 3 MONOOXYGENASE; NERVE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CAUDATE NUCLEUS; CELL COUNT; CELL DENSITY; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; GLIA CELL; IMMUNOHISTOCHEMISTRY; INFRARED RADIATION; MALE; MOUSE; NEAR INFRARED LIGHT; NEUROPROTECTION; NONHUMAN; PUTAMEN; RADIATION RESPONSE; STEREOLOGY; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; ASTROCYTE; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECTS; GLIOSIS; MPTP POISONING; PARKINSONIAN DISORDERS; PATHOLOGY; THERAPEUTIC USE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ASTROCYTES; CAUDATE NUCLEUS; CELL COUNT; CELL SURVIVAL; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; GLIOSIS; INFRARED RAYS; MALE; MICE; MICE, INBRED BALB C; MPTP POISONING; NERVE TISSUE PROTEINS; PARKINSONIAN DISORDERS; PARS COMPACTA; PUTAMEN; TYROSINE 3-MONOOXYGENASE;

EID: 84949254983     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2014.994063     Document Type: Article

References (47)

1. Bergman H, Deuschl G. Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Mov Disord Off J Mov Disord Soc 2002;17(Suppl 3):S28-40.
2. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368-76.
3. Rinne JO. Nigral degeneration in Parkinson's disease. Mov Disord Off J Mov Disord Soc 1993;8(Suppl 1):S31-35.
4. Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 2000:62;63-88.
5. DeSmet KD, Paz DA, Corry JJ et al. Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg 2006;24:121-28.
6. DeSmet K, Buchmann E, Henry M et al. Near-infrared light as a possible treatment option for Parkinson's disease and laser eye injury. p716503-10. Available from: http://dx.doi.org/10.1117/12.803964
7. Hamblin MR, Demidova TN. Mechanisms of low level light therapy-an introduction. Proc SPIE 2006;6140:61001:1-12.
8. Chung H, Dai T, Sharma SK et al. The nuts and bolts of lowlevel laser (light) therapy. Ann Biomed Eng 2012;40:516-33.
9. Rojas J,Gonzalez-Lima F. Low-level light therapy of the eye and brain. Eye Brain 2011;3:49-67.
10. Quirk BJ, Desmet KD, Henry M et al. Therapeutic effect of near infrared (NIR) light on Parkinson's disease models. Front Biosci Elite Ed 2012;4:818-23.
11. Johnstone D, Coleman K, Moro C et al. The potential of light therapy in Parkinson's disease. Chrono Physiol Ther 2014;4:1-14.
12. Liang HL, Whelan HT, Eells JT et al. Near-infrared light via light-emitting diode treatment is therapeutic against rotenoneand 1-methyl-4-phenylpyridinium ion-induced neurotoxicity. Neuroscience 2008;153:963-74.
13. Ying R, Liang HL, Whelan HT et al. Pretreatment with nearinfrared light via light-emitting diode provides added benefit against rotenone-and MPP+-induced neurotoxicity. Brain Res 2008;1243:167-73.
14. Trimmer PA, Schwartz KM, BorlandMKet al. Reduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy. Mol Neurodegener 2003;4:26.
15. Shaw VE, Spana S, Ashkan K et al. Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment. J Comp Neurol 2010;518:25-40.
16. Peoples C, Spana S, Ashkan K et al. Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson's disease. Parkinsonism Relat Disord 2012;18:469-76.
17. Moro C, Torres N, El Massri N et al. Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains. BMC Neurosci 2013;14:40.
18. Moro C, Massri NE, Torres N et al. Photobiomodulation inside the brain: A novel method of applying nearinfrared light intracranially and its impact on dopaminergic cell survival in MPTP-treated mice. J Neurosurg 2014;120: 673-80.
19. Johnstone DM, Massri NE, Moro C et al. Indirect application of near infrared light induces neuroprotection in a mouse model of parkinsonism-an abscopal neuroprotective effect. Neuroscience 2014;274:93-101.
20. Purushothuman S, Nandasena C, Johnstone DM et al. The impact of near-infrared light on dopaminergic cell survival in a transgenic mouse model of parkinsonism. Brain Res 2013;1535:61-70.
21. Strömberg I, Björklund H, Dahl D et al. Astrocyte responses to dopaminergic denervations by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as evidenced by glial fibrillary acidic protein immunohistochemistry. Brain Res Bull 1986;17:225-36.
22. Reinhard JF Jr, Miller DB, O'Callaghan JP. The neurotoxicant MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) increases glial fibrillary acidic protein and decreases dopamine levels of the mouse striatum: evidence for glial response to injury. Neurosci Lett 1998;95:246-51.
23. Francis JW, Von Visger J, Markelonis GJ et al. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol Teratol 1995;17:7-12.
24. Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I et al.Microglial reaction inMPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. J Neurodegener Disord 1996;5:137-43.
25. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I et al. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 1998;39:167-80.
26. Fernagut PO, Diguet E, Bioulac B et al. MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration. Exp Neurol 2004;185:47-62.
27. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004;318:215-24.
28. Gibrat C, Saint-Pierre M, Bousquet M et al. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and α-synuclein inclusions. J Neurochem 2009;109:1469-82.
29. Bové J, Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience 2012;211:51-76.
30. Piallat B, Benazzouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996;8:1408-14.
31. Wallace BA, Ashkan K, Heise CE et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 2007;130:2129-45.
32. Ma J, Shaw VE, Mitrofanis J. Does melatonin help save dopaminergic cells in MPTP-treated mice? Parkinsonism Relat Disord 2009;15:307-14.
33. Austin PJ, Beyer K, Bembrick AL et al. Peripheral nerve injury differentially regulates dopaminergic pathways in the nucleus accumbens of rats with either "pain alone" or "pain and disability". Neuroscience 2010;171:329-43.
34. Javoy-Agid F,Hirsch EC, Dumas S et al.Decreased tyrosine hydroxylasemessenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study. Neuroscience 1995;38:245-53.
35. Jackson-Lewis V, Jakowec M, Burke RE et al. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurodegener Disord 1995;4:257-69.
36. Björklund A, Rosenblad C, Winkler C et al. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 1997;4: 186-200.
37. Wu DC, Jackson-Lewis V, Vila M et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002;22:1763-71.
38. Lapchak PA. Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. Ann Med 2010;42;576-86.
39. Begum R, Powner MB,HudsonNet al. Treatment with 670 nm light up regulates cytochrome C oxidase expression and reduces inflammation in an age-related macular degeneration model. PloS One 2013;8:e57828.
40. Fallon JH, Loughlin SE. Monoamine innervation of the forebrain: collateralization. Brain Res Bull 1982;9:295-307.
41. Bezard E, Jaber M, Gonon F et al. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur J Neurosci 2000;12:2892-2900.
42. Costa LG, Aschner M. The role of glia in MPTP toxicity and Parkinson's disease. In: AschnerMand Costa LG eds., The role of glia in neurotoxicity. Chapter 27. 2nd Ed. Google eBook, Boca Raton, FL: CRC Press Inc; 2004.
43. McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord 2002;23:474-83.
44. Rappold PM, Tieu K. Astrocytes and therapeutics for Parkinson's disease. Neurotherapeutics 2010;7:413-23.
45. Episcopo FL, Tirolo C, Testa N et al. Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson's disease: focus on endogenous neurorestoration. Curr Aging Sci 2013;6:45-55.
46. Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. 2nd ed. San Diego: Academic Press; 2001.
47. Rouach N, Koulakoff A, Glaume C.Neurons set the tone of gap junctional communication in astrocytic networks. Neuochem Int 2004;45:265-72.